Lonza

💰 $445,713,738 Post-IPO Debt about 1 year agoPharmaceuticalBiotechnologyLife Science
Website LinkedIn Email Facebook Twitter

Lonza Group AG is a leading Life Sciences driven chemical company that provides active ingredients, chemical intermediates, and biotechnology solutions for the pharmaceutical and agrochemical sectors. With a focus on custom manufacturing and biopharmaceuticals, Lonza operates in three main divisions: Exclusive Synthesis & Biopharmaceuticals, Organic Fine & Performance Chemicals, and Polymer Intermediates, offering a wide range of products and services including microbial fermentation, therapeutic monoclonal antibodies, and various organic chemicals.

Related companies:

🏢 Keywords Studios
💰 Post-IPO Equity 7 months ago🫂 Last layoff over 1 year agoAudioVideo GamesDigital MediaContent
Website LinkedIn Facebook Twitter